-
公开(公告)号：US11213385B2
公开(公告)日：2022-01-04
申请号：US16154353
申请日：2018-10-08
发明人： Jeffrey S. Dove , Bin Tian , Ralph Schneider , Jeffrey S. Cohen , Ivan Jankovic , John F. Migliazza , Gregory A. Wright , James M. Young , Louis A. Campbell
摘要： Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.
-
公开(公告)号：US20190151083A1
公开(公告)日：2019-05-23
申请号：US16253051
申请日：2019-01-21
摘要： A method for manufacturing a heart valve using bioprosthetic tissue that exhibits reduced in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
-
公开(公告)号：US20180147323A1
公开(公告)日：2018-05-31
申请号：US15879339
申请日：2018-01-24
CPC分类号： A61L27/3625 , A61F2/2412 , A61F2210/0004 , A61F2210/0076 , A61L27/3683 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20 , A61L2430/40
摘要： A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing. In one method, tissue leaflets in assembled bioprosthetic heart valves are preconditioned by simulating actual flow conditions for a predetermined number of cycles, during or after which the valve is exposed to the capping agent.
-
公开(公告)号：US09029418B2
公开(公告)日：2015-05-12
申请号：US14139367
申请日：2013-12-23
CPC分类号： A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
摘要： A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
摘要翻译： 用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。 该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。 此外，该方法可用于抑制脱水组织中的氧化。 封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。 在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。
-
公开(公告)号：US08748490B2
公开(公告)日：2014-06-10
申请号：US13745496
申请日：2013-01-18
IPC分类号： A61F2/00
CPC分类号： A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
摘要： A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
摘要翻译： 用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。 该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。 此外，该方法可用于抑制脱水组织中的氧化。 封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。 在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。
-
公开(公告)号：US20130310929A1
公开(公告)日：2013-11-21
申请号：US13950154
申请日：2013-07-24
发明人： Jeffrey S. Dove , Bin Tian , Ralph Schneider , Jeffrey S. Cohen , Ivan Jankovic , John F. Migliazza , Gregory A. Wright , James Young , Louis A. Campbell
IPC分类号： A61F2/24
CPC分类号： A61F2/2415 , A61B18/20 , A61F2/02 , A61F2/24 , A61F2/2409 , A61F2/2418 , A61F2002/30324 , A61F2250/0036 , A61L27/3604 , A61L27/3625 , A61L27/3691 , A61L27/507 , A61L2300/60 , A61L2430/20 , B65B55/18 , B65B63/02
摘要： Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.
-
公开(公告)号：US20130134064A1
公开(公告)日：2013-05-30
申请号：US13745496
申请日：2013-01-18
IPC分类号： A61L27/36
CPC分类号： A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
摘要： A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
摘要翻译： 用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。 该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。 此外，该方法可用于抑制脱水组织中的氧化。 封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。 在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。
-
公开(公告)号：US10350064B2
公开(公告)日：2019-07-16
申请号：US15483786
申请日：2017-04-10
发明人： Amy E. Munnelly , Jeffrey S. Dove , Minsey Lee
IPC分类号： A61F2/24
摘要： An assembly and methods for providing a contoured biological tissue are described. The assembly comprises a first plate and a second plate. The first plate is configured to receive a biological tissue. The second plate is configured to contact and compress the biological tissue received on the first plate. One or both of the first and second plates comprise a defined shape and a contoured area within the defined shape. The contoured area comprises at least first and second elevations. One or more energy sources are associated with one or both of the first and second plates. The one or more energy sources deliver energy upon compression of the biological tissue.
-
公开(公告)号：US20170071731A1
公开(公告)日：2017-03-16
申请号：US15357990
申请日：2016-11-21
发明人： Jeffrey S. Dove , Bin Tian , Ralph Schneider , Jeffrey S. Cohen , Ivan Jankovic , John F. Migliazza , Gregory A. Wright , James M. Young , Louis A. Campbell
CPC分类号： A61F2/2415 , A61B18/20 , A61F2/02 , A61F2/24 , A61F2/2409 , A61F2/2418 , A61F2002/30324 , A61F2250/0036 , A61L27/3604 , A61L27/3625 , A61L27/3691 , A61L27/507 , A61L2300/60 , A61L2430/20 , B65B55/18 , B65B63/02
摘要： Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.
摘要翻译： 生物假体材料调理方法采用牛心包膜。 指向膜的纤维表面并相对于其移动的激光将膜的厚度减小到特定的均匀厚度并平滑表面。 选择激光器的波长，功率和脉冲速率，这将使纤维表面平滑，并将表面烧蚀到合适的厚度。 或者，使用皮肤表面从膜的纤维表面去除一层材料。 变薄也可能采用压缩。 使用交联以稳定膜的逐步压缩来避免通过非弹性压缩损伤膜。 相反，膜通过加成交联结合在弹性压缩状态。 上述几种稀释技术可以一起使用以获得强的薄膜。
-
公开(公告)号：US09498288B2
公开(公告)日：2016-11-22
申请号：US13950154
申请日：2013-07-24
发明人： Jeffrey S. Dove , Bin Tian , Ralph Schneider , Jeffrey S. Cohen , Ivan Jankovic , John F. Migliazza , Gregory A. Wright , James Young , Louis A. Campbell
CPC分类号： A61F2/2415 , A61B18/20 , A61F2/02 , A61F2/24 , A61F2/2409 , A61F2/2418 , A61F2002/30324 , A61F2250/0036 , A61L27/3604 , A61L27/3625 , A61L27/3691 , A61L27/507 , A61L2300/60 , A61L2430/20 , B65B55/18 , B65B63/02
摘要： Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.032 秒)
